Ultragenyx Pharmaceutical (RARE) Cash & Equivalents (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Cash & Equivalents data on file, last reported at $175.0 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 37.8% year-over-year to $175.0 million in Q1 2026; TTM through Mar 2026 was $175.0 million, a 37.8% increase from a year earlier, with the FY2025 full-year figure at $421.0 million, up 141.95% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $175.0 million, down from $421.0 million in the prior quarter.
• Over the last five years, Cash & Equivalents for RARE reached as high as $480.7 million in Q2 2024 and fell as low as $72.6 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $196.0 million across 5 years, with a median of $159.9 million in 2022.
• Across the five-year window, Cash & Equivalents sank 81.47% in 2023 and surged 371.0% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $132.9 million in 2022, then surged by 60.97% to $214.0 million in 2023, then declined by 18.69% to $174.0 million in 2024, then soared by 141.95% to $421.0 million in 2025, then sank by 58.43% to $175.0 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $175.0 million in Q1 2026, $421.0 million in Q4 2025, and $202.5 million in Q3 2025.